<DOC>
	<DOCNO>NCT02499861</DOCNO>
	<brief_summary>This Phase I/IIa study test combination epigenetic drug decitabine isoflavone genistein child leukemias solid tumor . For phase I study , maximum tolerate dose evaluate pediatric patient relapse refractory leukemia solid tumor . For phase II study , patient relapse refractory leukemia include . To evaluate treatment efficacy gain insight action drug , DNA methylation level treatment participant , pharmacokinetics parameter level decitabine peak level genistein measure . Pharmacogenomics test decitabine perform prior cycle 1 treatment . Decitabine administer 24 hour infusion day 1 cycle ( 28 day ) genistein take orally twice daily day 2 21 , follow 7 day rest period .</brief_summary>
	<brief_title>Phase I/II Study Decitabine Combination With Genistein Pediatric Relapsed Refractory Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>Genistein</mesh_term>
	<criteria>Age ≥ 2 year age &lt; 21 year age time study enrollment Able swallow genistein take puree . Patients must diagnosis recurrent refractory solid tumor , include Central Nervous System tumor , lymphoma leukemia standard curative measure exist longer effective For solid tumor , patient must either measurable evaluable disease . For leukemia , patient must &gt; 5 % blast bone marrow . Patients must fully recover acute toxic effect prior anticancer therapy . Performance level : Karnofsky ≥50 % patient ≥ 16 year age Lansky ≥ 50 % patient &lt; 16 year age Life expectancy least one month Patients must adequate bonemarrow function Patients must normal organ define : ( total bilirubin ≤ 24microM/L ) , Amylase/pancreatic amylase≤1.5 × institutional upper limit normal , Aspartate Aminotransferase ( AST ) /Alanine Aminotransferase ( ALT ) ≤2.5 × institutional upper limit normal , creatinine clearance ≥60 mL/min/1.73 m2 . OR creatinine accord age/gender Nervous system disorder ( CTCAE v4 ) result prior therapy must ≤ Grade 2 Participants childbearing potential men must agree use adequate contraception duration study treatment , 4 month completion decitabine genistein administration . All patient and/or parent legally authorize representative must sign write informed consent Prior decitabine genistein therapy . Patients receive investigational agent . Nasogastric gastrostomy ( equivalent ) administration genistein allow . Patients know exclusive nonmeasurable leptomeningeal disease enrolment exclude clinical trial . History allergic reaction attribute compound similar chemical biologic composition decitabine genistein . Uncontrolled intercurrent illness include , limited , ongoing active infection ( receive antibiotic ) , symptomatic heart lung disease , psychiatric illness/social situation would limit compliance study requirement . Pregnant breastfeed woman exclude study . All girl child bear potential must negative pregnant test prior enrolment . Patients opinion investigator may able comply safety monitoring requirement study eligible .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>